BiotechTube

Pimecrolimus + Hydrocortisone + Pimecrolimus

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis

Trial Timeline

Apr 1, 2007 → Oct 1, 2009

NCT ID
NCT00507832

About Pimecrolimus + Hydrocortisone + Pimecrolimus

Pimecrolimus + Hydrocortisone + Pimecrolimus is a phase 2 stage product being developed by Novartis for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT00507832. Target conditions include Prurigo Nodularis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00507832Phase 2Completed

Competing Products

20 competing products in Prurigo Nodularis

See all competitors
ProductCompanyStageHype Score
Vixarelimab + PlaceboKiniksa PharmaceuticalsPhase 2
47
UpadacitinibAbbVieApproved
85
Rocatinlimab + PlaceboAmgenPhase 3
76
AbrocitinibPfizerPhase 2
51
Dupilumab SAR231893 (REGN668)SanofiPre-clinical
22
DupilumabSanofiPhase 3
76
DupilumabSanofiPre-clinical
22
DupilumabSanofiPre-clinical
22
Ruxolitinib Cream 1.5%IncytePhase 1
30
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
INCB054707 + PlaceboIncytePhase 2
49
Povorcitinib + PlaceboIncytePhase 3
74
Povorcitinib + PlaceboIncytePhase 3
74
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
CDX-0159 + Normal salineCelldex TherapeuticsPhase 1
28
barzolvolimabCelldex TherapeuticsPhase 2
47
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
60
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine ER Tablets + Placebo TabletsTrevi TherapeuticsPhase 2/3
60
serlopitant + PlaceboVyne TherapeuticsPhase 2
44

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85